Home › Lung Cancer › Texas › Fort Worth
Lung Cancer clinical trials in Fort Worth, TX
3 studies for Lung Cancer are looking for participants at sites in and around Fort Worth (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Texas Oncology - DFW, Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Start - Dfw, Fort Worth
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 3
- JPS Health Network, Fort Worth
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH37 studies
- Philadelphia, PA36 studies
Other studies in Fort Worth
- Non-Small Cell Lung Cancer18 studies
- Ovarian Cancer17 studies
- Endometrial Cancer12 studies
- Breast Cancer11 studies
- Cancer (all types)9 studies
- Prostate Cancer9 studies
- Heart Failure7 studies
- Colorectal Cancer7 studies
- Triple-Negative Breast Cancer7 studies
- Metastatic Cancer7 studies
- Kidney Cancer (Renal Cell Carcinoma)7 studies
- Ulcerative Colitis7 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.